Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MSI-H/dMMR + TMB-H

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related biomarkers:

‹

›

MSI-H/dMMR + TMB-H	Solid Tumor	MSI-H/dMMR + TMB-H	Solid Tumor	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2wk	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + TMB-H	Colorectal Cancer	MSI-H/dMMR + TMB-H	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MSI-H/dMMR + TMB-H	Prostate Cancer	MSI-H/dMMR + TMB-H	Prostate Cancer	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4
MSI-H/dMMR + TMB-H	HER2 Positive Breast Cancer	MSI-H/dMMR + TMB-H	HER2 Positive Breast Cancer	pembrolizumab + trastuzumab Sensitive: C4 – Case Studies pembrolizumab + trastuzumab Sensitive : C4	pembrolizumab + trastuzumab Sensitive: C4 – Case Studies pembrolizumab + trastuzumab Sensitive : C4
MSI-H/dMMR + TMB-H	Gastric Cancer	MSI-H/dMMR + TMB-H	Gastric Cancer	olaparib Sensitive: D – Preclinical olaparib Sensitive : D	olaparib Sensitive: D – Preclinical olaparib Sensitive : D